Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 2/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1119419 | 0.92 | SCN2A (0.33) | SCN2AGFERTRPV1 | |
| SCHEMBL1119587 | 0.90 | SCN2A (0.32) | SCN2AGFERTRPV1 | |
| SCHEMBL1119442 | 0.86 | GFER (0.46) | SCN2AGFERTRPV1KDM4ENPC1 | |
| SCHEMBL1119468 | 0.81 | — | — | |
| SCHEMBL4049587 | 0.72 | ALDH1A1 (0.41) | KDM4ENPC1POLBRAB9A | |
| SCHEMBL403894 | 0.71 | MTOR (0.43) | SCN2AKDM4ENPC1RAB9A | |
| SCHEMBL4015570 | 0.70 | SCN2A (0.55) | SCN2AKDM4ENPC1RAB9A | |
| SCHEMBL2651782 | 0.69 | DRD1 (0.42) | GFERNPC1RAB9AATM | |
| SCHEMBL2651748 | 0.64 | NOTUM (0.34) | — | |
| SCHEMBL6002502 | 0.64 | AHR (0.46) | KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895599-B2 | Lipoprotein lipase-activating compositions comprising benzene derivates | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20130296342-A1 | LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATES | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2013-11-07 | — | — | US | disclosed |
| EP-2280706-B1 | LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATIVES | OTSUKA PHARMA CO LTD (JP) | 2013-01-02 | — | — | EP | disclosed |
| US-20110065728-A1 | LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATIVES | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296342-A1 | LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATES | LPL, LIPC, LIPE | SCN2A 3801/4885GFER 1731/4885TRPV1 1126/4885 |
| US-20110065728-A1 | LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATIVES | LPL, LIPC, LIPE | SCN2A 3667/4885GFER 1844/4885TRPV1 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.